114 Dawn Health’s model reflects an important reality: patients do not experience healthcare in neat organisational silos. They move between research, treatment, monitoring and follow-up, often while managing chronic conditions that require continuous support. Digital tools can help bridge those gaps, but only if they are designed for compliance, usability and integration into broader healthcare ecosystems. Dawn Health has built a patient-centric product suite for the pharmaceutical industry that includes tools for disease management, therapy support and real-world evidence collection. Its platform is already used in areas such as oncology, multiple sclerosis and rare paediatric conditions, helping patients manage treatment, report symptoms and stay connected with care teams. What I find most compelling about these three companies is the way they map to a larger story about the future of life sciences. Discovery, development, commercialisation and patient engagement are often treated as separate domains, supported by different systems and different teams. But the organisations that will lead in the next decade are likely to think more holistically. They will look for ways to connect insight generation with operational execution and patient experience. Causaly, Biolevate and Dawn Health each address a different point in that continuum, but together they show what becomes possible when AI is applied with domain depth and enterprise discipline. They are not abstract examples of innovation; they are practical examples of how modern platforms can help life sciences companies move faster, work smarter and stay focused on outcomes that matter. Sally Ann Frank is global lead for health and life sciences at Microsoft for Startups VIEWPOINT Photo: AdobeStock/SOMKID
RkJQdWJsaXNoZXIy NzQ1NTk=